BILLERICA, Mass. --(BUSINESS WIRE)--Mar. 21, 2024-- Quanterix Corporation (NASDAQ: QTRX), a leading provider of ultra-sensitive research products and high-definition diagnostics, today announced a specific partnership path for laboratories interested in offering Tau based research and diagnostic

BILLERICA, Mass. --(BUSINESS WIRE)--Mar. 4, 2024-- Quanterix Corporation (NASDAQ: QTRX), a leading provider of ultra-sensitive research products and high-definition diagnostics, announced today that its Simoa ® phospho-Tau 217 (p-Tau 217) blood test has been granted Breakthrough Device designation

BILLERICA, Mass. --(BUSINESS WIRE)--Feb. 29, 2024-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the fourth quarter and twelve months ended December 31, 2023 .

BILLERICA, Mass. --(BUSINESS WIRE)--Feb. 26, 2024-- Quanterix Corporation (NASDAQ: QTRX) today announced that it has rescheduled the release of its financial results for the fourth quarter and year ended December 31, 2023 and the associated conference call in order to more closely align the release

AdventHealth, Mass General Brigham , Mayo Clinic , MUSC, and UPMC will leverage Quanterix technology and assays to streamline care for Alzheimer’s patients BILLERICA, Mass. --(BUSINESS WIRE)--Feb. 26, 2024-- Quanterix Corporation (NASDAQ: QTRX), a leading provider of ultra-sensitive research

BILLERICA, Mass. --(BUSINESS WIRE)--Feb. 23, 2024-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will present at Cowen’s 44th Annual Health Care Conference .

BILLERICA, Mass. --(BUSINESS WIRE)--Feb. 16, 2024-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced it will host a conference call on Tuesday, February 27, 2024 , to discuss its fourth quarter earnings and full